Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Conference attendees have access to Convergence on-demand content until 31 January 2022.
Keep the sparks coming! Delegates of the conference have access to on-demand content until the end of October 2021.
Hone in on the sector knowledge you need with RAPS' Fundamentals of Pharmaceutical and Biologics Regulations and Fundamentals of Medical Device Regulations.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 12 January 2015 | By Michael Mezher
Regulators in China are looking to allow online sales of prescription medicines starting in early 2015, according to Reuters. A senior healthcare policy worker told the publication the China Food and Drug Administration (CFDA), “Is actively working on [the policy].”
Presently, state-run nonprofit hospitals sell about 70% of all prescription drugs sold in China. The rest are purchased through retail pharmacy locations. The new policy could work to liberalize pharmaceutical distribution in China by opening up a new avenue for prescription drugs sales.
It is unclear how China will regulate online sales of prescription drugs; however, it appears that at least initially the drugs sold online will be limited to those on a government list. It also remains to be seen whether the policy will allow for direct-to-consumer sales, business-to-business, or through a government or middleman-run hub.
Online pharmaceutical sales are nothing new in China, and many jurisdictions regulate what types of drugs may be sold online. The Internet is also a major source for black market drugs (anyone who regularly checks their spam folder can attest to this) whose safety and efficacy cannot be vouched for. Drugs purchased through rogue or unregulated online pharmacies run the risk of being counterfeit, adulterated, misbranded or mislabeled, which can result in serious unintended side effects or death.
By creating a regulated environment for online pharmacies, regulators can provide legal alternatives to rogue pharmacies on the web.
In spring 2014, China’s National Development and Reform Commission (NDRC) announced it would be lifting price controls set on over 500 low-cost and essential drugs. The move was seen as an effort to ease shortages of a number of drugs following a highly publicized shortage of the hyperthyroid drug Tapazole. Some experts cautioned that removing the price controls may not reduce shortages, citing China’s Centralized Bidding Procurement (CBP) process as a source of pricing pressure. In China, all state-run hospitals are required to use the CBP when purchasing most types of drugs.
Reuters
Regulatory Focus newsletters
All the biggest regulatory news and happenings.